Cargando…

Validating GAN-BioBERT: A Methodology for Assessing Reporting Trends in Clinical Trials

BACKGROUND: The aim of this study was to validate a three-class sentiment classification model for clinical trial abstracts combining adversarial learning and the BioBERT language processing model as a tool to assess trends in biomedical literature in a clearly reproducible manner. We then assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Myszewski, Joshua J., Klossowski, Emily, Meyer, Patrick, Bevil, Kristin, Klesius, Lisa, Schroeder, Kristopher M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170913/
https://www.ncbi.nlm.nih.gov/pubmed/35685304
http://dx.doi.org/10.3389/fdgth.2022.878369
_version_ 1784721537725628416
author Myszewski, Joshua J.
Klossowski, Emily
Meyer, Patrick
Bevil, Kristin
Klesius, Lisa
Schroeder, Kristopher M.
author_facet Myszewski, Joshua J.
Klossowski, Emily
Meyer, Patrick
Bevil, Kristin
Klesius, Lisa
Schroeder, Kristopher M.
author_sort Myszewski, Joshua J.
collection PubMed
description BACKGROUND: The aim of this study was to validate a three-class sentiment classification model for clinical trial abstracts combining adversarial learning and the BioBERT language processing model as a tool to assess trends in biomedical literature in a clearly reproducible manner. We then assessed the model's performance for this application and compared it to previous models used for this task. METHODS: Using 108 expert-annotated clinical trial abstracts and 2,000 unlabeled abstracts this study develops a three-class sentiment classification algorithm for clinical trial abstracts. The model uses a semi-supervised model based on the Bidirectional Encoder Representation from Transformers (BERT) model, a much more advanced and accurate method compared to previously used models based upon traditional machine learning methods. The prediction performance was compared to those previous studies. RESULTS: The algorithm was found to have a classification accuracy of 91.3%, with a macro F1-Score of 0.92, significantly outperforming previous studies used to classify sentiment in clinical trial literature, while also making the sentiment classification finer grained with greater reproducibility. CONCLUSION: We demonstrate an easily applied sentiment classification model for clinical trial abstracts that significantly outperforms previous models with greater reproducibility and applicability to large-scale study of reporting trends.
format Online
Article
Text
id pubmed-9170913
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91709132022-06-08 Validating GAN-BioBERT: A Methodology for Assessing Reporting Trends in Clinical Trials Myszewski, Joshua J. Klossowski, Emily Meyer, Patrick Bevil, Kristin Klesius, Lisa Schroeder, Kristopher M. Front Digit Health Digital Health BACKGROUND: The aim of this study was to validate a three-class sentiment classification model for clinical trial abstracts combining adversarial learning and the BioBERT language processing model as a tool to assess trends in biomedical literature in a clearly reproducible manner. We then assessed the model's performance for this application and compared it to previous models used for this task. METHODS: Using 108 expert-annotated clinical trial abstracts and 2,000 unlabeled abstracts this study develops a three-class sentiment classification algorithm for clinical trial abstracts. The model uses a semi-supervised model based on the Bidirectional Encoder Representation from Transformers (BERT) model, a much more advanced and accurate method compared to previously used models based upon traditional machine learning methods. The prediction performance was compared to those previous studies. RESULTS: The algorithm was found to have a classification accuracy of 91.3%, with a macro F1-Score of 0.92, significantly outperforming previous studies used to classify sentiment in clinical trial literature, while also making the sentiment classification finer grained with greater reproducibility. CONCLUSION: We demonstrate an easily applied sentiment classification model for clinical trial abstracts that significantly outperforms previous models with greater reproducibility and applicability to large-scale study of reporting trends. Frontiers Media S.A. 2022-05-24 /pmc/articles/PMC9170913/ /pubmed/35685304 http://dx.doi.org/10.3389/fdgth.2022.878369 Text en Copyright © 2022 Myszewski, Klossowski, Meyer, Bevil, Klesius and Schroeder. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Digital Health
Myszewski, Joshua J.
Klossowski, Emily
Meyer, Patrick
Bevil, Kristin
Klesius, Lisa
Schroeder, Kristopher M.
Validating GAN-BioBERT: A Methodology for Assessing Reporting Trends in Clinical Trials
title Validating GAN-BioBERT: A Methodology for Assessing Reporting Trends in Clinical Trials
title_full Validating GAN-BioBERT: A Methodology for Assessing Reporting Trends in Clinical Trials
title_fullStr Validating GAN-BioBERT: A Methodology for Assessing Reporting Trends in Clinical Trials
title_full_unstemmed Validating GAN-BioBERT: A Methodology for Assessing Reporting Trends in Clinical Trials
title_short Validating GAN-BioBERT: A Methodology for Assessing Reporting Trends in Clinical Trials
title_sort validating gan-biobert: a methodology for assessing reporting trends in clinical trials
topic Digital Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170913/
https://www.ncbi.nlm.nih.gov/pubmed/35685304
http://dx.doi.org/10.3389/fdgth.2022.878369
work_keys_str_mv AT myszewskijoshuaj validatingganbiobertamethodologyforassessingreportingtrendsinclinicaltrials
AT klossowskiemily validatingganbiobertamethodologyforassessingreportingtrendsinclinicaltrials
AT meyerpatrick validatingganbiobertamethodologyforassessingreportingtrendsinclinicaltrials
AT bevilkristin validatingganbiobertamethodologyforassessingreportingtrendsinclinicaltrials
AT klesiuslisa validatingganbiobertamethodologyforassessingreportingtrendsinclinicaltrials
AT schroederkristopherm validatingganbiobertamethodologyforassessingreportingtrendsinclinicaltrials